Karolinska Development has sold its remaining stake in BioArctic, which is based on research at Uppsala University and floated on Nasdaq Stockholm last year.
Karolinska Development, the venture capital arm of Karolinska Institute, sold its remaining shareholding in BioArctic, a Sweden-based biopharmaceutical firm based on research at Uppsala University.
Karolinska sold more than half a million shares for a total of Skr12m ($1.4m). The firm had already sold $3.9m worth of stock in November 2017 shortly after BioArctic listed on Nasdaq Stockholm.
Founded in 2003, BioArctic was initially focusing on Alzheimer’s disease but has since also used its platform to develop treatments for other…
